NEW YORK (GenomeWeb News) – Compugen and Roche have agreed to collaborate in an effort to search for biomarkers that could help predict patient responses to drugs aimed at treating rheumatoid arthritis, Compugen said Thursday.
Compugen will use its GeneVa database, which holds around 200,000 non-SNP genetic variations, to investigate DNA samples for markers that could predict response or non-response to selected drugs Roche intends to develop.
GeneVa includes algorithms and other computational biology tools to find variations that are associated with specific phenotypes that may be linked to particular drug responses.
Financial terms of the agreement were not released.